Atazanavir: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Atazanavir}} | |||
{{CMG}}; {{AE}} {{MM}} | |||
==Overview== | |||
==Category== | |||
==US Brand Names== | |||
REYATAZ<sup>®</sup> | |||
==FDA Package Insert== | |||
'''[[Atazanavir description|Description]]''' | |||
'''| [[Atazanavir clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Atazanavir microbiology|Microbiology]]''' | |||
'''| [[Atazanavir indications and usage|Indications and Usage]]''' | |||
'''| [[Atazanavir contraindications|Contraindications]]''' | |||
'''| [[Atazanavir warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Atazanavir adverse reactions|Adverse Reactions]]''' | |||
'''| [[Atazanavir overdosage|Overdosage]]''' | |||
'''| [[Atazanavir dosage and administration|Dosage and Administration]]''' | |||
'''| [[Atazanavir how supplied|How Supplied]]''' | |||
==Mechanism of Action== | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 16:16, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Category
US Brand Names
REYATAZ®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied